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ABSTRACT
Objective To determine rates of faecal
biomarker results capable of suggesting
potentially treatable causes of irritable bowel
syndrome (IBS) symptomatology in a population
of patients with symptoms of IBS who meet
Rome III criteria for that condition.
Design Descriptive, retrospective study in which
faecal biomarker results (dichotomised into
‘normal’ and ‘abnormal’ values) were related to
data from patient-completed questionnaire data
identifying demographics, Rome III criteria for IBS
and IBS phenotype (IBS-D, IBS-C, IBS-M and IBS-U).
Setting Commercial reference laboratory.
Patients Individuals whose physicians ordered
faecal biomarker testing for evaluation of chronic
abdominal symptoms consistent with IBS.
Interventions None.
Main outcome measures Rates of occurrence of
abnormal results on any of seven faecal
biomarkers suggesting a treatable cause for IBS
symptoms.
Results Abdominal symptoms meeting Rome III
criteria for IBS were present in 3553 records (the
population), which were subjected to further
analysis. Abnormal biomarker results (the
outcomes) occurred in 94% of cases; 73% and
65% of records indicated growth of a bacterial
potential pathogen and low growth of beneficial
organisms, respectively. Abnormal results for all
other faecal biomarkers occurred with
frequencies from 5% to 13%. Frequency of
abnormal results for elastase, calprotectin,
eosinophil protein X, and beneficial organisms
rose significantly with age, and differed
significantly across IBS phenotypes.
Conclusions A large proportion of patients
manifesting symptoms meeting Rome III IBS
diagnostic criteria have faecal biomarker results
indicating potential underlying, treatable causes
of their symptoms. Faecal biomarker testing is an
appropriate means of identifying potentially
treatable causes of IBS symptoms.
INTRODUCTION
Abdominal symptoms consistent with irrit-
able bowel syndrome (IBS) are highly
prevalent and impose substantial burdens
on sufferers and the healthcare system in
general. A positive diagnosis can be made
using Rome Foundation criteria for IBS, but
such clinical criteria do not offer guidance
on management of any individual patient’s
condition, leading to continued use of inva-
sive and costly diagnostic imaging techni-
ques that produce meaningful results in
only a small fraction of cases.1 2
Current evidence indicates that symp-
toms associated with IBS, including those
contributing to a positive diagnosis by
Rome III and other clinical criteria, fre-
quently arise from a number of independ-
ent, and often treatable, conditions.3 The
actual frequency of the presence of such
underlying causes of IBS symptoms,
however, remains unknown.
In the present study, therefore, we
attempted to characterise the frequency
and distribution of results for seven faecal
biomarkers capable of suggesting under-
lying conditions that could be responsible
for producing symptoms in accordance
with those diagnostic criteria, in a group
of subjects with chronic abdominal pain
meeting current Rome III IBS criteria.
METHODS
This study was a retrospective, observa-
tional evaluation of faecal biomarker
results in a population of subjects with
abdominal pain, verified by a validated,
self-administered questionnaire to have
IBS by Rome III criteria.
Setting
The study was conducted by Genova
Diagnostics (GDX, Asheville, North
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Carolina, USA), a commercial CLIA-certified reference
laboratory. GDX routinely includes a validated, self-
report Rome III IBS questionnaire in all collection kits
used for faecal biomarker testing.
During the study period, from April 2013 to March
2014, all records for which patient questionnaires
were completed were eligible for inclusion.
Questionnaires were prelabelled with bar codes that
associated them with faecal specimens for results
reporting. For this study, all data were stripped of
patient identifying information prior to analysis, and
no protected health information was recorded for
study purposes. Thus, the data set for analysis
included results of faecal biomarker testing, age,
gender and results of the Rome III survey only. Results
of the Rome III survey were used to identify subjects
who met Rome III criteria for IBS, and to categorise
them by IBS phenotype.
Patient population
GDX serves a predominantly US-based ambulatory
patient population; faecal biomarker testing is typic-
ally ordered by primary care physicians when patients
present with gastrointestinal (GI) symptoms without
obvious cause. Thus, records included in this study
represent a ‘real world’ population selected by
primary care providers who use faecal biomarker
testing provided by GDX in response to their con-
cerns about potential sources of GI symptomatology.
For this study, only patients whose age was indi-
cated as ≥18 years, who had faecal testing for any of
the biomarkers of interest, and whose Rome III ques-
tionnaire provided a positive diagnosis of IBS were
included. Not every Rome III-confirmed subject had
every biomarker ordered on test requisitions. There
was no study-mandated intervention; the ordering of
faecal biomarker tests was at the discretion of the
referring physician.
Faecal biomarkers
Based on previous work, we selected seven target
biomarkers each of which produced abnormal results
in more than 2% of subjects with abdominal symp-
toms consistent with IBS (table 1).4 The clinical val-
idity and diagnostic performance of these target
biomarkers have been summarised in other published
studies.5–12
Statistical analyses
Faecal biomarker results were dichotomised into
‘normal’ and ‘abnormal’ categories based on the
cut-offs shown in table 1. Frequency distributions for
abnormal results were prepared for each biomarker
and for other study variables, including age, gender
and Rome III IBS subcategory. Differences in distribu-
tion of abnormal biomarker results between age,
gender, and IBS subcategories were analysed by Chi-
square for significance.
Table 1 Targeted faecal biomarkers in patients with Rome III-confirmed IBS
Biomarker Assay used Definition of abnormal result
Interpretation of abnormal
result in context of IBS
Culture for pathogenic or
potentially pathogenic
bacteria*
Routine culture. Present. Suggestive of GI pathogenic
disease.
Culture for beneficial
bacteria (Lactobacillus,
Bifidobacterium)
Routine culture. Growth in 1 or fewer quadrants
(Lacto)/2 or fewer quadrants (Bifido).
Reduced numbers of beneficial
symbionts (dysbiosis).13 14
Pancreatic elastase-1 Monoclonal antibody EIA (Pancreatic
elastase 1 stool test, ScheBo Biotech USA,
Colorado Springs, Colorado, USA).
<200 μg/g Suggestive of exocrine pancreatic
insufficiency.
Calprotectin ELISA, PhiCal, Lysaker, Norway. >50 μg/g Suggestive of neutrophilic
inflammation, for example, IBD.
Eosinophil protein X Modified EDN sandwich ELISA†, MBL
International, Woburn, Massachusetts,
USA.
>7 μg/g Suggestive of food allergy or
parasites (or other causes of
eosinophilic inflammation).
Parasites‡ EIA for Entamoeba histolytica/dispar,
Giardia lamblia, Cryptosporidium; light
microscopy for all other parasites.
E. histolytica/dispar, G. lamblia,
Cryptosporidium: EIA-positive§,
Blastocystis hominis: present on
microscopic exam, all other parasites:
present on microscopic exam.
Occult blood Hemosure one-step iFOB test, (Hemosure
Irwindale, California, USA).
Present. Suggestive of inflammation,
malignancy, enteric infection.
Seven biomarkers were chosen for determination of prevalence of abnormal results in a Rome III-confirmed IBS population. All of these have been reported
as evidence of potential aetiological roles in production of IBS symptoms.
*See online supplementary table 1 for bacterial/fungal pathogen designations.
†Laboratory-derived test (LDT) based on.10
‡See online supplementary table 2 for parasite pathogen designations.
§Detection by ELISA (EIA).
EDN, eosinophil-derived neurotoxin; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; iFOB, immunochemical faecal occult blood; MBL,
Medical and Biological Laboratories Co, Ltd.
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RESULTS
A total of 24 258 faecal specimens were received
during the study period. Of those, 7503 included
completed demographic surveys; calculation of a true
survey response rate was not possible because it could
not be confirmed that all specimen collection kits in
use during the study period included survey forms.
The flow diagram in figure 1 illustrates further selec-
tion of records based on age and record completion
data.
After exclusion of records missing age and Rome III
data, and selection of those indicating IBS by Rome
III criteria, 3553 records were included for further
analysis.
Gender, age and Rome III subcategory distributions
The study population of 3553 subjects consisted of
2860 (80.5%) women and 693 (19.5%) men. There
were 1892 (53.3%) 18–49-year-old subjects, with
1348 (37.9%) aged 50–69 years, and 313 (8.8%)
aged 70 years or greater.
Figure 2 shows the distribution of Rome III subcat-
egories of IBS in the total population of Rome
III-confirmed subjects.
General distribution of abnormal biomarker results
Figure 3 shows the frequency of abnormal biomarker
results in the entire Rome III-confirmed study popula-
tion; not all subjects were tested for all biomarkers,
therefore, the total number of subjects tested for each
biomarker appears in parentheses.
Tests for the biomarkers pancreatic elastase-1
(PE-1), faecal calprotectin (FC) and eosinophil protein
X (EPX) produce continuous results, with ‘abnormal’
being defined as values above or below clinically rele-
vant cut-offs as shown in table 2.
We examined possible relationships between several
individual biomarkers. For example, elevated levels of
EPX and FC or the presence of faecal occult blood
(FOB) may each indicate mucosal inflammation and
parasitosis may cause inflammation. In our cohort
only 48.9% (112/229) of subjects with elevated EPX
levels also had an elevated FC value. In IBS subjects
with a documented parasite, 7.3% (14/193), 4.3% (9/
210) and 3.1% (3/97) had an abnormal FC, EPX or
FOB, respectively.
Distribution of abnormal biomarker results by gender
There was a significant gender effect on several of the
biomarkers studied. There were significantly more
male than female subjects with abnormal PE-1 results
(17.2% vs 12.4%, p<0.001). A small but significant
female predominance was seen in abnormally low
levels of growth of Bifidobacteria/Lactobacillus, with
abnormal results in 67.3% of women versus 57.1% in
men (p<0.001). All other abnormalities were evenly
gender distributed.
Distribution of abnormal biomarker results by age
The frequency of abnormal results for several individ-
ual biomarkers rose significantly with increasing age
categories, as shown in table 3. Subjects in the middle
age group (50–69 years) had significantly greater fre-
quency of abnormal commensal organisms (low
growth of Bifidobacteria/Lactobacillus), compared
with the youngest and oldest groups.
No significant age effects were seen on the rates of
abnormal results for occult blood, parasites or bacter-
ial potential pathogens.
Distribution of abnormal biomarkers by Rome III IBS
subcategory
Table 4 shows significant differences in the occurrence
of abnormal faecal biomarker results by Rome III IBS
subcategory (the category IBS-U included only 32
records (0.9%), and was dropped from subsequent
analyses).
No significant effects of IBS subcategory were seen
in rates of abnormal results for FOB, parasites or
PE-1. There were no significant differences by Rome
III subcategory for having abnormal results for the
outcome ‘any abnormal’ (IBS-C, 24.4%, IBS-D,
28.8%, IBS-M 25.0%).
DISCUSSION
The present study represents, to our knowledge, the
largest population of patients with Rome
III-confirmed IBS in which a complete characterisa-
tion of demographics and IBS subtypes has been
attempted, and the only one to date in which an array
of faecal biomarker results has been described. As
noted, there was no control group; this study was not
intended to evaluate the discriminatory power of any
of the biomarkers as diagnostic of IBS; in fact, subjects
in whom abnormal biomarkers were detected would
be candidates for an alternate diagnosis based on
those results, and a broader workup, potentially
including endoscopy in certain cases, would be
appropriate.
The principal findings in this study are that the rate
of abnormal results on the faecal biomarkers evalu-
ated is quite high, at 94% overall; we identified sig-
nificant differences in faecal biomarker patterns
occurring by age category, and by IBS phenotype.
This study confirms and strengthens our previous
findings in a study of patients with presumed IBS
based on ICD-9 codes alone,4 demonstrating quite
similar distributions of abnormal biomarker results in
a population confirmed to have IBS by Rome III cri-
teria. The current study also includes analyses of bio-
marker results by Rome III subcategories, and presents
a more detailed distribution of results of biomarker
tests returning continuous results.
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Implications of abnormal biomarkers in an IBS population
Changes in our understanding of IBS have led to the
recognition that the syndrome is unlikely to have a
single, identifiable cause, but also that it ought no
longer to be considered a diagnosis of exclusion.
Rather, the notion that IBS is an ‘umbrella’ diagnosis
of a phenotype defined by symptoms that are
common to a number of discrete disease processes has
gained currency.3 15
In the present study, we have taken initial steps to
characterise a group of biomarkers capable of
suggesting alternative, treatable conditions or under-
lying causes producing the IBS phenotype as defined
by Rome III criteria. The intention is to improve out-
comes of patients classified as meeting IBS criteria by
identifying and treating reversible disorders.
Ultimately, it is to be hoped that faecal biomarker
testing will have the effect of shrinking the number of
patients in whom the diagnosis of IBS, without
further specification, is the end point of the diagnostic
evaluation.
Our analysis suggests that parallel assessment of
multiple biomarkers may have significant clinical
utility in differentiating specific underlying aetiologies
of IBS presentations. For example, FC and EPX (asses-
sing neutrophilic inflammation and eosinophilic
inflammation, respectively) appear to be independent
biomarkers. This finding is consistent with other pub-
lished studies demonstrating that EPX may be a
marker of treatment response in collagenous colitis,
which is thought to have more eosinophilic involve-
ment than inflammatory bowel disease (IBD).16 17
Consistent with our previous work in a non-Rome
III-confirmed IBS population,4 we identified a high
overall rate of abnormal findings on selected faecal
biomarkers. The two microbiota-related biomarkers,
bacterial potential pathogens and abnormal growth of
Figure 1 Flow diagram of sample selection and reduction of subject numbers by application of exclusion criteria. ‡Data from
Medical Record; ‡‡Records missing gender and age data were not identical. *Δ Gender: p<0.001; **Δ Age: p<0.001; ***Δ Age:
p<0.05.
Figure 2 Distribution of ROME-III irritable bowel syndrome
(IBS) subcategories in the study sample of 3553 individuals.
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the beneficial commensals Bifidobacteria and
Lactobacillus, accounted for a large proportion of
abnormal results. These are non-standard biomarkers,
and accurate values for their rates in healthy popula-
tions are not known, so it is possible that these find-
ings have relatively little significance.
On the other hand, there is increasing evidence
from other studies that community-level dysbiosis is a
highly prevalent, important and potentially contribu-
tory factor to IBS, particularly in the diarrhoea-
predominant subtype.15 18
Others have shown, using 16S rRNA gene sequen-
cing by PCR, that significant phylotype-level altera-
tions exist in the intestinal microbiota of patients with
IBS in comparison with control subjects, that such dif-
ferences persist between certain IBS subtypes, and that
patients with IBS carry microbiota of significantly less
biodiversity than do healthy control subjects.19–24
These studies appear to suggest that our culture-
based result may indeed be a rough indicator of
shifted microbial patterns in IBS, and make a case for
further study using our faecal biomarkers in combin-
ation with advanced microbiome genomic sequencing.
Implications of abnormal biomarkers by IBS subtype
We found substantial differences between IBS sub-
groups in terms of biomarker results. Patients in the
IBS-D subcategory had significantly higher rates of
abnormal calprotectin, EPX and bacterial potential
pathogens, compared with the IBS-C and IBS-M
Figure 3 Distribution of abnormal biomarker results in study sample (N=3553). Note that any individual may have had zero, one or
more than one abnormal result, and that not every individual had every biomarker tested.
Table 3 Proportion (%) of subjects with abnormal results by
age
Biomarker 18–49 50–69 70+
Pancreatic elastase* 9.2 16.8 23.1
Calprotectin** 9.7 12.0 17.8
Eosinophil protein X* 7.2 9.0 17.0
Low growth of Bifido/Lacto*** 62.9 69.3 62.6
Age distribution of abnormal results for biomarkers with significant
differences by age.
Across-group significance: *p<0.0001; **p=0.0009; ***p<0.0025.
Table 2 Distribution of results for continuous biomarkers
PE-1 Count (N=2628) Per cent
≥200 2278 86.68
101–199 234 8.90
≤100 116 4.41
Total abnormal results 350 13.3
FC Count (N=2667) Per cent
≤50 2367 88.75
51–120 161 6.04
>120 139 5.21
Total abnormal results 300 11.25
EPX Count (N=2656) Per cent
≤2 1904 71.69
>2≤7 520 19.58
>7 232 8.73
Total abnormal results 232 8.73
EPX, eosinophil protein X; FC, faecal calprotectin; PE-1, pancreatic
elastase-1.
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groups. Compared with IBS-M, patients in the IBS-D
and IBS-C groups had significantly higher and lower
rates of abnormal calprotectin and EPX, respectively.
These findings appear to suggest biological differences
between these subgroups, and to represent greater
inflammatory responses in patients with IBS-D than in
patients with IBS-C.
Subjects in the IBS-D group also had a higher rate of
bacterial potential pathogens (see online
supplementary table 1) compared with patients with
IBS-M, though the numerical difference was small.
Given that these were culture-based results, and that
the definition of ‘potential pathogen’ is to some extent
arbitrary, further study of the composition of the entire
GI microbiome might shed clearer light on the role of
various bacterial taxa in the etiopathogenesis of IBS.
Our findings in these regards appear consistent with
previous work by others suggesting that patients with
IBS-D have higher rates of both low-grade inflamma-
tion and dysbiosis.
Future studies should focus on the clinical utility of
faecal biomarkers in management of patients whose
symptoms meet Rome III criteria for IBS. It has already
been shown using retrospective medical claims analysis
that a structured faecal biomarker panel can reduce
healthcare costs and unnecessary utilisation of services
in evaluating patients with abdominal symptoms con-
sistent with having IBS.25 It is to be anticipated that
such a structured panel, composed of carefully selected
biomarkers, will be shown prospectively to improve
patient outcomes by directing management strategies
towards the underlying, treatable causes of IBS symp-
toms, and at the same time to reduce utilisation of
invasive and costly diagnostic procedures.
Application of faecal biomarkers in clinical
decision-making for patients with IBS
It is important to recognise that the clinical utility, in
terms of negative and positive predictive values (NPV,
PPV, respectively) of any diagnostic test is dependent
on the prevalence of the condition of interest in the
population under discussion. Values for NPV and PPV
in the literature are frequently misleading, because
they are typically derived from prevalence figures in
populations with high concentrations of the condition
of interest, whereas in unselected clinical populations,
the prevalence, and, hence, the predictive values, may
be considerably different.26
Using published prevalence figures in patients with
IBS seen in primary care settings for endocrine pancre-
atic insufficiency (6.1%27) and neutrophilic inflamma-
tion (eg, IBD (1%28)), and the published performance
characteristics of the PE-1 and FC assays used in this
current study,5 8 9 it is readily shown that the NPVs of
both biomarkers are greater than 99%, while the PPV
of FC is relatively low, confirming its known use as a
screening test to rule out inflammatory processes.9
On the other hand, PE-1 has, using these same
assumptions, a PPV of 46.3%. This suggests that the
PE-1 assay could serve to identify a subset of patients
with IBS in whom a trial of pancreatic enzyme therapy
is worthwhile, treating only about one patient who
does not have exocrine pancreatic insufficiency (EPI)
for each one correctly managed.
Additional potential biomarkers in assessment of patients
with IBS
As IBS is increasingly recognised as a syndrome with
multiple, possibly interacting, underlying causes, we
anticipate the emergence of additional biomarkers
that may be of substantial clinical utility in
management.
For example, bile acid malabsorption (BAM) has
been shown to be present in 25% or more of patients
meeting clinical criteria for IBS, especially those with
the IBS-D phenotype.29 30 The established standard
for making the diagnosis of BAM is the
23-seleno-25-homotaurocholic acid test (SeHCAT),
which is time-consuming and, while approved in most
European countries, is as yet unavailable in the
USA.31 Other studies, such as the 14C glycocholate
test, involve radiation exposure, and may have diffi-
culty in differentiation BAM from small intestinal bac-
terial overgrowth (SIBO), while measurement of
serum 7 α-hydroxy-4-cholesten-3-one (C4) lacks suffi-
cient clinical validation.31
Direct measurement of bile acids in faecal matter
may provide a simpler means of detecting BAM in
patients with IBS, and elevated levels of faecal bile
acids have indeed been identified in both patients
with IBS-D and functional diarrhoea.31 32 Total faecal
bile acid levels appear to have clinical validity,
showing significant association with SeHCAT reten-
tion at day 3, and a good correlation (r=0.606) with
serum C4 levels.31 A further potential advantage of
direct faecal bile acid measurement is that low, rather
than high levels of bile acids have been associated
with IBS-C and functional constipation.31 33 34
Increased intestinal permeability (IP) has also
recently been associated with syndrome-defining
symptoms of IBS, and has been detected in mucosa of
patients with IBS.35 Zonulin is a peptide signalling
molecule that disrupts tight junctional proteins
Table 4 Proportion (%) of subjects with abnormal results by IBS
subcategory
Biomarker IBS-D IBS-C IBS-M
Calprotectin* 13.4‡ 7.1‡ 10.9
Eosinophil protein X** 12.2‡‡ 4.4‡‡ 8.0
Low growth of Bifido/Lacto*** 64.1 71.6‡‡‡ 64.6
Bacterial potential pathogens**** 75.9‡‡‡‡ 71.0 71.6
Across-group significance: *p=0.0025; **p<0.001; ***p=0.0402;
****p=0.0285.
Between-group significance, versus IBS-M: ‡p<0.004; ‡‡p<0.003;
‡‡‡p=0.0114; ‡‡‡‡p=0.0103.
IBS, irritable bowel syndrome.
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between intestinal mucosal cells, leading to increased
intestinal permeability (IIP).36 Serological testing for
zonulin has been demonstrated to correlate well with
gold-standard lactulose/mannitol testing in patients
with increased IP from several causes (R2=0.7935).37
A recent study, published to date in abstract form
only, has demonstrated elevated blood zonulin levels
in subjects with IBS-D.38
Intestinal dysbiosis, as noted above, is a common
finding in patients with IBS.39 40 Improving accessibil-
ity of real-time, multiplex PCR sequencing may yet
prove a useful biomarker of dysbiosis, which has been
shown to respond well symptomatically to therapy
with certain specific probiotic preparations such as B.
infantis 35624.41–43
Finally, symptoms of IBS induced by SIBO appear
to respond well to treatment with the non-absorbed
antibiotic rifaximin, increasing the need for a reliable
and convenient biomarker of this condition. Several
such biomarkers have recently been identified by
Pimentel et al,44–46 who suggest that antibodies
against cytolethal distending toxin B and vinculin
have potential utility in distinguishing IBS-D from
IBD; the immunological targets of these antibodies
are known to be produced by bacteria that cause acute
gastroenteritis and have been identified in animal
models of postinfectious IBS.
As the role of various treatable conditions in
patients meeting symptom criteria for IBS grows, it
seems likely that these and other biomarkers will be
of increasing interest in evaluating such patients and
formulating targeted treatment plans.
Limitations
This was a retrospective study, comprised of data from
subjects whose physicians ordered faecal biomarker
testing as part of their clinical evaluation for abdominal
symptoms. Thus, it is susceptible to selection biases,
and is not presented as a true cross-sectional study rep-
resentative of the general population of patients with
IBS. This study does, however, represent the largest
population of patients with Rome III-confirmed IBS
described in detail, including data on faecal biomarker
patterns. We therefore believe that, despite these lim-
itations, it significantly extends our knowledge of the
nature and characteristics of IBS.
Additionally, with a large number of patients being
studied with a range of biomarkers, there is a danger
of type I error. However, the biological plausibility of
the types of biomarker profiles seen with specific ‘IBS’
phenotypes suggests that this is less likely.
Conclusions
This study showed a high rate of abnormal results on
faecal biomarker testing, further confirming previous
findings and supporting the concept of IBS as an
‘umbrella’ diagnosis with a suite of symptoms produced
in common by a number of different and potentially
treatable underlying causes. Future prospective studies
may further delineate subpopulations with potentially
treatable causes of symptoms consistent with IBS, ultim-
ately shrinking the pool of patients in whom ‘IBS’ repre-
sents a diagnostic stopping point, instead refining
diagnostic procedures and guiding therapy.
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